Hims & Hers, a peptide and GLP-1 play, could make a big move this week because heavy short interest of 33.6% meets a very tight chart setup. After a big move up and a pullback, the stock sits on key longer-term levels and is riding its moving averages, tight enough to structure a trade at 5:1 reward to risk or better. It is a non-traditional setup for this style of trading. x.com 

Hims & Hers' peptide capabilities may be underappreciated, setting up a strong bounce after peptide news. Per @riyadosofian, it is the only telehealth company with a peptide facility and global distribution system. A strong bounce is expected now as the stock holds outside its wedge. x.com  x.com 

Hims & Hers is a meme stock, not a fundamental story, after missing EPS by 1,440%, with earnings down 300% year over year and 600% quarter over quarter. The company pays influencers to pump the stock, and even a move to $200 would not change that view. x.com  x.com 

Hims & Hers looks bullish after its first open-market insider buy in years, because insiders sell for various reasons but buy for only one. Per @himshouse, director David B. Wells, formerly Netflix's CFO, bought 48.4k shares for $1.2 million. A monthly close above $25 is all Hims & Hers needs. x.com 

Hims & Hers has enormous long-term potential from its brand, personalized platform and recurring model, and that upside heavily outweighs the bear case. Regulation and customer retention are real questions, and they explain why the opportunity exists. x.com 

Hims & Hers is uninvestable without trust in its management team, and there is absolutely no confidence in it. The stock looked overvalued at $60 before its steep fall; as a popular retail stock it could return to $60 or beyond, but distrust of management rules it out. x.com 

Hims & Hers is going higher after its report as growth comes back nicely. The EPS miss was mostly a legal contingency charge, a nothing burger, so shares should rise within weeks if not the next day. x.com  x.com  x.com 

Hims & Hers' compounding direct-to-consumer distribution makes it stupidly undervalued next to Tempus AI. Hims has $2.6B in trailing revenue at a $6.7B market cap, with 66.5% annual revenue growth from Q3 2021 to Q2 2026; Tempus has $1.4B in revenue, a $14.9B market cap and 40.4% annual growth. x.com 

Hims & Hers is going through a major transition period with no growth, so it is not worth owning right now, even though the long-term view remains bullish. x.com 

Hims & Hers' growth is on sale at a PEG of about 0.8 because last year's crash left the stock cheap. Revenue grew 40% to $753M last quarter and full-year guidance was raised to $3.3B; sub-1 PEGs are usually born from drawdowns like that. x.com